{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:01:57Z","timestamp":1792180917896,"version":"4.4.0"},"reference-count":73,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background\/objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in treating type 2 diabetes and obesity, offering established metabolic and cardiovascular benefits. Emerging evidence suggests these agents also exert direct dermatologic effects. This systematic review categorizes these effects and explores their role in inflammatory skin diseases. Methods: A comprehensive literature search was performed across EMBASE, PubMed, Web of Science, and Google Scholar for studies published from 2014 to 2025. Inclusion criteria were English-language, peer-reviewed original research involving human subjects that linked GLP-1RAs to dermatologic effects. Animal and in vitro studies were excluded. PRISMA guidelines were followed. Results: Fifty-one studies met inclusion criteria. Thirty-four reported adverse effects, including hypersensitivity, injection-site reactions, pruritus, urticaria, angioedema, and immune-mediated conditions like bullous pemphigoid. Seventeen studies described beneficial outcomes, such as improvements in psoriasis, reduced hidradenitis suppurativa flares, enhanced wound healing, anti-aging potential, and decreased inflammation. GLP-1RAs showed cytokine modulation in psoriasis, though their role in hidradenitis suppurativa remains uncertain. Cosmetic concerns, such as \u201cOzempic Face\u201d due to rapid weight loss, were also noted. Conclusions: GLP-1RAs have a broad spectrum of dermatologic effects, from immunomodulatory benefits to adverse cutaneous reactions. Their impact on inflammatory skin disorders suggests a novel therapeutic avenue. However, adverse reactions and aesthetic changes warrant vigilance. Future research should focus on mechanistic studies, long-term safety, and identifying biomarkers to predict dermatologic responses, ultimately guiding personalized treatment approaches.<\/jats:p>","DOI":"10.3390\/diseases13050127","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T04:22:08Z","timestamp":1745295728000},"page":"127","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["A Closer Look at the Dermatological Profile of GLP-1 Agonists"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9548-8094","authenticated-orcid":false,"given":"Calista","family":"Persson","sequence":"first","affiliation":[{"name":"Dr. Kiran Patel College of Osteopathic Medicine, Nova Southeastern University, Davie, FL 33328, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Eaton","sequence":"additional","affiliation":[{"name":"Dr. Kiran Patel College of Osteopathic Medicine, Nova Southeastern University, Davie, FL 33328, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2690-7922","authenticated-orcid":false,"given":"Harvey N.","family":"Mayrovitz","sequence":"additional","affiliation":[{"name":"Dr. Kiran Patel College of Allopathic Medicine, Nova Southeastern University, Davie, FL 33314, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40257-018-0400-7","article-title":"Cutaneous adverse effects of diabetes mellitus medications and medical devices: A review","volume":"20","author":"Jedlowski","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/diabetology3010008","article-title":"Cutaneous reactions to antidiabetic agents: A narrative review","volume":"3","author":"Boccardi","year":"2022","journal-title":"Diabetology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: A systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: Systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2147\/CLEP.S456170","article-title":"Semaglutide (Ozempic\u00ae) use in Denmark 2018 through 2023\u2014User trends and off-label prescribing for weight loss","volume":"16","author":"Mailhac","year":"2024","journal-title":"Clin. Epidemiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ajem.2024.01.010","article-title":"GLP-1 agonists: A review for emergency clinicians","volume":"78","author":"Long","year":"2024","journal-title":"Am. J. Emerg. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s11695-023-06971-y","article-title":"Popularity of surgical and pharmacological obesity treatment methods searched by google users: The retrospective analysis of google trends statistics in 2004\u20132022","volume":"34","year":"2024","journal-title":"Obes. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e146625","DOI":"10.5812\/jssc-146625","article-title":"Cutaneous adverse drug reactions to antidiabetic medications and medical devices used in management of diabetes mellitus","volume":"11","author":"George","year":"2024","journal-title":"J. Skin. Stem Cell."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1021\/jm500810s","article-title":"Glucagon-like peptide-1 (GLP-1) analogs: Recent advances, new possibilities, and therapeutic implications","volume":"58","author":"Manandhar","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s40265-021-01499-w","article-title":"A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes","volume":"81","author":"Andersen","year":"2021","journal-title":"Drugs"},{"key":"ref_13","first-page":"4020492","article-title":"GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes","volume":"2018","year":"2018","journal-title":"J. Diabetes Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e235663","DOI":"10.1136\/bcr-2020-235663","article-title":"Extending our understanding of exenatide: A rare case of angio-oedema","volume":"14","author":"Mahfooz","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2015","journal-title":"Rev. Diabet. Stud. RDS"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"230624","DOI":"10.1155\/2012\/230624","article-title":"Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: A mixed treatment comparison meta-analysis","volume":"2012","author":"Sun","year":"2012","journal-title":"Exp. Diabetes Res."},{"key":"ref_17","first-page":"e20041","article-title":"A rare case of dulaglutide-associated angioedema in a male patient","volume":"13","author":"Karakousis","year":"2021","journal-title":"Cureus"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: A randomized-controlled trial","volume":"33","author":"Lin","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_19","first-page":"21-0007","article-title":"Two birds one stone: Semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient","volume":"2021","author":"Costanzo","year":"2021","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.anai.2022.08.735","article-title":"The first report of angioedema and anaphylaxis with temporal association to semaglutide","volume":"129","author":"Feinstein","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e70003","DOI":"10.1002\/der2.70003","article-title":"Semaglutide \u201cOzempic\u201d face and implications in cosmetic dermatology","volume":"5","author":"Montecinos","year":"2024","journal-title":"Dermatol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.36849\/JDD.7613","article-title":"Natural weight loss or \u201cOzempic Face\u201d: Demystifying a social media phenomenon","volume":"1","author":"Carboni","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/ijd.17246","article-title":"GLP-1 agonists and hair loss: A call for further investigation","volume":"63","author":"Desai","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.12788\/cutis.1148","article-title":"Dermatologic Implications of glycemic control medications for patients with type 2 diabetes mellitus","volume":"115","author":"Ponce","year":"2025","journal-title":"Cutis"},{"key":"ref_25","first-page":"1","article-title":"Risk of suicide, hair loss, and aspiration with GLP1-receptor agonists and other diabetic agents: A real-world pharmacovigilance study","volume":"39","author":"Nakhla","year":"2024","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"81-LB","DOI":"10.2337\/db23-81-LB","article-title":"81-LB: Novel microsphere technology reducing injection site reaction in the development of long-acting GLP-1 RA formulation","volume":"72","author":"Kim","year":"2023","journal-title":"Diabetes"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.diabres.2018.10.013","article-title":"Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K\/Akt pathway in keratinocytes","volume":"146","author":"Nagae","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1111\/jocd.16514","article-title":"Advancements in laser technologies for skin rejuvenation: A comprehensive review of efficacy and safety","volume":"23","author":"Haykal","year":"2024","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2337\/ds20-0033","article-title":"Injection-site nodules associated with once-weekly subcutaneous administration of semaglutide","volume":"34","author":"Hearn","year":"2021","journal-title":"Diabetes Spectr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Marino-Fern\u00e1ndez, A.G., Garc\u00eda-Guti\u00e9rrez, I., Alonso Juaristi, S., L\u00f3pez Guti\u00e9rrez, J., Tawfiq Piedad, M., Guerrero Sotelo, \u00c1.L., Albarrac\u00edn Contreras, \u00c1.J., Ortiz Aljaro, P., and Rodr\u00edguez Fern\u00e1ndez, F. (2024). Hypersensitivity to liraglutide: A case report. Asia Pac. Allergy, 10.5415.","DOI":"10.5415\/apallergy.0000000000000149"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/jdds.jdds_5_19","article-title":"Liraglutide-induced injection site reaction","volume":"23","author":"Neel","year":"2019","journal-title":"J. Dermatol. Dermatol. Surg."},{"key":"ref_33","first-page":"23","article-title":"Cellulitis at GLP-1 agonist injection site: Rare but relevant","volume":"17","author":"Simoes","year":"2022","journal-title":"Rev. Port. Diabetes"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/ijd.14272","article-title":"Pyoderma gangrenosum associated with dulaglutide therapy","volume":"58","author":"Hamann","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/DAD.0000000000000243","article-title":"Exenatide-induced eosinophil-rich granulomatous panniculitis: A novel case showing injected microspheres","volume":"37","year":"2015","journal-title":"Am. J. Dermatopathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1684\/ejd.2019.3691","article-title":"An unusual case of a generalized cutaneous drug reaction to liraglutide","volume":"29","author":"Bovijn","year":"2019","journal-title":"Eur. J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jdcr.2023.06.010","article-title":"Delayed type hypersensitivity injection site reaction and tolerance induction to liraglutide for the treatment of obesity","volume":"38","author":"Yaneva","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_38","first-page":"e21536","article-title":"An uncommon case of dulaglutide-related morbilliform drug eruption","volume":"14","author":"Kyriakos","year":"2022","journal-title":"Cureus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-0044-1788934","article-title":"Rare liraglutide-induced dermatological adverse reaction in the treatment of obesity","volume":"7","author":"Alam","year":"2024","journal-title":"J. Diabetes Endocr. Pract."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101552","DOI":"10.1016\/j.diabet.2024.101552","article-title":"Cutaneous hypersensitivity reaction to dulaglutide: A case report of an allergic reaction","volume":"50","author":"Samhani","year":"2024","journal-title":"Diabetes Metab."},{"key":"ref_41","first-page":"13","article-title":"A Case of morbilliform drug eruption to dulaglutide","volume":"13","author":"Rzepka","year":"2020","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_42","first-page":"9676","article-title":"Bullous pemphigoid triggered by dulaglutide: A case report and a review of the literature","volume":"15","author":"Sonego","year":"2023","journal-title":"Dermatol. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jdcr.2021.07.027","article-title":"Semaglutide-associated bullous pemphigoid","volume":"15","author":"Burruss","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.12788\/cutis.0262","article-title":"Bullous pemphigoid triggered by liraglutide","volume":"107","author":"Collins","year":"2021","journal-title":"Cutis"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s13300-016-0187-6","article-title":"Lipodystrophy in insulin-treated subjects and other injection-site skin reactions: Are we sure everything is clear?","volume":"7","author":"Gentile","year":"2016","journal-title":"Diabetes Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/DAD.0000000000000036","article-title":"Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site","volume":"36","author":"Shan","year":"2014","journal-title":"Am. J. Dermatopathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1001\/jamadermatol.2019.1893","article-title":"Acute photodistributed exanthematous pustulosis associated with liraglutide treatment","volume":"155","author":"Cogen","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdcr.2024.08.018","article-title":"Eczematous liraglutide eruption managed by dupilumab: A case report","volume":"53","author":"Paganini","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1007\/s10067-023-06612-w","article-title":"Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): A case report and review of the literature","volume":"42","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/8755122514539462","article-title":"Systemic allergic reaction to the GLP-1 receptor agonist exenatide","volume":"30","author":"Steveling","year":"2014","journal-title":"J. Pharm. Technol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"53683","DOI":"10.12775\/QS.2024.17.53683","article-title":"Challenges and risks of using GLP-1 antagonists in treating type 2 diabetes and obesity","volume":"17","author":"Plizga","year":"2024","journal-title":"Qual. Sport."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"NP809","DOI":"10.1093\/asj\/sjae132","article-title":"Decoding the implications of glucagon-like peptide-1 receptor agonists on accelerated facial and skin aging","volume":"44","author":"Ridha","year":"2024","journal-title":"Aesthetic Surg. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bjps.2024.07.051","article-title":"The rise of \u201cOzempic Face\u201d: Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists","volume":"96","author":"Mansour","year":"2024","journal-title":"J. Plast. Reconstr. Aesthetic Surg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bjps.2023.04.057","article-title":"Ozempic face: A new challenge for facial plastic surgeons","volume":"81","author":"Tay","year":"2023","journal-title":"J. Plast. Reconstr. Aesthetic Surg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.2023.2438","article-title":"As Ozempic\u2019s popularity soars, here\u2019s what to know about semaglutide and weight loss","volume":"329","author":"Suran","year":"2023","journal-title":"Jama"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"ojae069","DOI":"10.1093\/asjof\/ojae069","article-title":"Soft tissue facial changes following massive weight loss secondary to medical and surgical bariatric interventions: A systematic review","volume":"Volume 6","author":"Jafar","year":"2024","journal-title":"Aesthetic Surgery Journal Open Forum"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1016\/j.jid.2021.05.015","article-title":"GLP-1 analogs and SGLT2 inhibitors do not increase risk of bullous pemphigoid","volume":"141","author":"Varpuluoma","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Petkovi\u0107-Dabi\u0107, J., Bini\u0107, I., Cari\u0107, B., Bo\u017ei\u0107, L., Umi\u010devi\u0107-\u0160ipka, S., Bednar\u010duk, N., Dabi\u0107, S., \u0160itum, M., Popovi\u0107-Peji\u010di\u0107, S., and Stojiljkovi\u0107, M.P. (2025). Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: An open-label, randomized clinical trial. Biomolecules, 15.","DOI":"10.3390\/biom15010046"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00592-011-0359-9","article-title":"Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide","volume":"51","author":"Faurschou","year":"2014","journal-title":"Acta Diabetol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diabres.2019.03.002","article-title":"Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study","volume":"150","author":"Xu","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ad.2023.06.017","article-title":"Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases","volume":"115","author":"Vilarrasa","year":"2021","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Krajewski, P.K., Z\u0142otowska, A., and Szepietowski, J.C. (2024). The Therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: A systematic review of anti-inflammatory and metabolic effects. J. Clin. Med., 13.","DOI":"10.3390\/jcm13216292"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40257-024-00911-x","article-title":"Obesity in hidradenitis suppurativa: Are GLP-1 receptor agonists the new frontier?","volume":"26","author":"Strong","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/ijd.16892","article-title":"Therapeutic potential of GLP-1 agonists for hidradenitis suppurativa","volume":"62","author":"Henry","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"ref_65","first-page":"16527","article-title":"The first case of the exacerbation of psoriatic skin lesions after liraglutide","volume":"133","author":"Nowowiejska","year":"2023","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2147\/PTT.S485061","article-title":"Impact of GLP-1 receptor agonists on psoriasis and cardiovascular comorbidities: A narrative review","volume":"14","author":"Haran","year":"2024","journal-title":"Psoriasis Targets Ther."},{"key":"ref_67","unstructured":"Latif, W., Lambrinos, K.J., Patel, P., and Rodriguez, R. (2024). Compare and Contrast The Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs), StatPearls."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/JW9.0000000000000143","article-title":"A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists","volume":"10","author":"Ogunremi","year":"2024","journal-title":"Int. J. Women\u2019s Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1073\/pnas.1601653113","article-title":"Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery","volume":"113","author":"Yang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/oby.23772","article-title":"Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function","volume":"31","author":"Khalil","year":"2023","journal-title":"Obesity"},{"key":"ref_71","unstructured":"(2025, March 21). Anodyne Nanotech Achieves Breakthrough in Transdermal Delivery of GLP-1 Drugs. Available online: https:\/\/www.businesswire.com\/news\/home\/20241219119563\/en\/Anodyne-Nanotech-Achieves-Breakthrough-in-Transdermal-Delivery-of-GLP-1-Drugs."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10787-024-01602-z","article-title":"Naturally derived bioactive compounds as precision modulators of immune and inflammatory mechanisms in psoriatic conditions","volume":"33","author":"Radu","year":"2025","journal-title":"Inflammopharmacology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e15248","DOI":"10.1111\/dme.15248","article-title":"Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study","volume":"41","author":"Pradhan","year":"2024","journal-title":"Diabet. Med."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/5\/127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:19:10Z","timestamp":1760030350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/5\/127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":73,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["diseases13050127"],"URL":"https:\/\/doi.org\/10.3390\/diseases13050127","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]}}}